Masaki Sudo
President and CEO

Thank you for visiting our website.

Since its establishment, TMRC Co., Ltd has been dedicated to drug discovery and development, specializing in the development of anti-cancer drugs. Our main pipeline, tamibarotene (TM-411), a retinoic acid receptor agonist licensed to Syros Pharmaceuticals Inc., advanced onto clinical development as a treatment for blood cancer. However, in November 2024, Syros Pharmaceuticals Inc. announced the discontinuation of clinical development.

Despite this situation, we firmly believe that the knowledge and experience cultivated through our past research and development are valuable assets for our company. Moving forward, we will utilize these experiences to explore new possibilities and sincerely advance our business to fulfill our responsibilities through the relationship with our valued stakeholders.